Cambridge Healthtech Institute’s 4th Annual

Improving Immunotherapy Efficacy and Safety

Developing Targeted, Safe Immunotherapies

April 8-9, 2019

 

Immunotherapies represent a step-change in cancer treatment, yet questions still remain around their efficacy, targeting and toxicity. Cambridge Healthtech Institute’s Improving Immunotherapy Efficacy and Safety conference details the latest developments in immunotherapy, including established and emerging targets and modalities, new engineering strategies, combinations, biomarkers, effective preclinical models and strategies to mitigate toxicity and recent clinical developments. Examples will come from the world of checkpoint inhibitors, adoptive T cell therapy, combinations and oncolytic viruses. We will also investigate manipulating the tumor microenvironment and emerging IO targets.

Preliminary Agenda

ADVANCES IN CHECKPOINTS

PD-1 Antibodies Are Transforming Cancer Treatment Both as Mono and Combination Therapy

Roy Baynes, MD, PhD., Senior Vice President, Global Clinical Development & CMO, Merck Research Labs

Best-In-Class PD-1 Pathway Blockade with Efficacy Against Cold Tumors

Michael Curran, PhD., Assistant Professor, Department of Immunology, MD Anderson Cancer Centre

Third-Generation Immune Checkpoint Inhibitors and Development of AB154, A Clinical-Stage TIGIT Antibody

Juan C. Jaen, PhD., President, Arcus Biosciences, Inc.

Immunotherapy for Cancer: The Need for More Effective Combination Therapies

Ronald Herbst, PhD, Vice President, R&D and Head, Oncology Research, MedImmune

Evolutionary Dynamics of the Immune Response to Cancer: Implications for Immunotherapy

Brad Nelson, PhD, Co-Director, Immunotherapy Program, BC Cancer Agency

NEXT-GENERATION IMMUNOTHERAPY

NK cells: Growing up to Become Safe and Efficacious Cellular Therapeutics?

Hans Klingemann, MD, PhD, VP, Research and Development, NantKwest Inc.

Reprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting

Theodore Roth, PhD., Student, Marson Laboratory, UCSF

Controllable CAR T Cell Therapy

Travis Young, PhD., VP, Biologics, CALIBR

Novel Strategies to Mitigate Toxicities After Chimeric Antigen Receptor T Cell Therapy

Saad J. Kenderian, Assistant Professor, Medicine and Oncology, Mayo Clinic College of Medicine

Presentation to be Announced


Luncheon Presentation: Target Specificity Screening of CAR T Cells Using Human Cell Microarray Technology

Alex Kelly, US Business Development Manager, Retrogenix Limited


* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean




Premier Sponsors


View By: